<DOC>
	<DOCNO>NCT01633112</DOCNO>
	<brief_summary>The purpose study compare 2 dos ( 0.25 mg 0.50 mg ) fingolimod glatiramer acetate ( 20 mg ) evaluate efficacy fingolimod 0.25 mg treatment patient relapsing-remitting MS ( RRMS ) .</brief_summary>
	<brief_title>MS Study Evaluating Safety Efficacy Two Doses Fingolimod Versus Copaxone</brief_title>
	<detailed_description>This multicenter , randomize , rater- dose-blinded , study compare efficacy safety 0.25 mg 0.5 mg fingolimod glatimer acetate 20 mg s.c. patient RRMS . This study consist 3 period : - Screening Period : 1 month patient - Treatment Period : 12 month glatiramer acetate 20 mg , fingolimod 0.25 mg , fingolimod 0.5 mg - Follow-up occur 3 month ( 12 week ) last dose study drug patient After sign informed consent , patient enter Screening Period determine eligibility study . After inclusion/exclusion criterion review safety assessment conduct , patient enter Treatment Period randomly assign 1 3 group 1:1:1 ratio : - Group 1 receive fingolimod 0.5 mg orally day 12 month - Group 2 receive fingolimod 0.25 mg orally day 12 month - Group 3 receive glatiramer acetate 20 mg subcutaneously day 12 month</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Inclusion criterion : Written inform consent must obtain assessment perform Male female patient 18 65 year age , inclusive . Patients RRMS , define 2010 revise McDonald criterion . Patients must neurologically stable onset relapse steroid use within 30 day randomization Patients least 1 documented relapse previous year 2 documented relapse previous 2 year randomization . Patients EDSS score 0 6 inclusive Screening . A score 6.0 indicate unilateral assistance ( cane crutch ) require walk least 100 meter without rest . Patients treat interferon beta glatimer acetate continue treatment randomization Exclusion criterion : Patients history malignancy organ system ( cutaneous basal cell carcinoma ) Patients active chronic disease ( stable treat immune therapy ) immune system MS ( e.g. , rheumatoid arthritis , scleroderma , Sjogren 's syndrome , Crohn 's disease , ulcerative colitis ) know immunodeficiency syndrome ( HIVantibody positive , AIDS , hereditary immune deficiency , druginduced immune deficiency ) . Patients treat : Highdose intravenous ( IV ) immunoglobulin ( Ig ) within 2 month randomization Immunosuppressive/chemotherapeutic medication ( e.g. , azathioprine , cyclophosphamide , methotrexate ) within 6 month randomization Monoclonal antibody ( include natalizumab ) within 6 month randomization Rituximab , alemtuzumab , ofatumumab , ocrelizumab , mitoxantrone cladribine time randomization Patients treat corticosteroid adrenocorticotropic hormone past 30 day screen visit Patients uncontrolled diabetes mellitus ( HbA1c &gt; 7 % ) Patients diagnosis macular edema Screening ( patient history macular edema allow enter study provide macular edema Screening ) Positive screen serological marker hepatitis A , B , C , E indicate acute chronic infection : Patients negative varicella zoster virus IgG antibody Screening Patients receive live live attenuate vaccine ( include varicella zoster virus , herpes simplex , measles ) within 1 month randomization Patients receive total lymphoid irradiation bone marrow transplantation Patients unstable medical/psychiatric condition , assess primary treat physician site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>